Skip to content
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文（繁體）
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Language
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
Substrate deprivation therapy...
Cite this
Text this
Email this
Print
Export Record
Export to RefWorks
Export to EndNoteWeb
Export to EndNote
Permanent link
Substrate deprivation therapy reduces brain ganglioside content and GM1 in neonatal storage disease mice
Bibliographic Details
Main Authors:
Kasperzyk, J
,
Hauser, E
,
D'Azzo, A
,
Platt, F
,
Seyfried, T
Format:
Conference item
Published:
2002
Holdings
Description
Similar Items
Staff View
Similar Items
N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis.
by: Kasperzyk, J, et al.
Published: (2004)
Effects of substrate deprivation therapy on brain lipids in neonatal GML storage disease mice
by: Kasperzyk, J, et al.
Published: (2003)
Therapeutic assessment of substrate deprivation using NB-DGJ in GM1 storage disease mice
by: Seyfried, T, et al.
Published: (2003)
Substrate reduction therapy reduces brain ganglioside GM2 in neonatal Sandhoff disease mice
by: Baek, R, et al.
Published: (2005)
N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice.
by: Baek, R, et al.
Published: (2008)